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INTRODUCTION 
INTRODUCTION
Drug drug interactions can be defined as the modifications of the effects of one drug
i.e.the  object  drug  by  the  prior  or  concomitant  administration  of  another  drug  i.e  the
precipitant.It is also defined as a pharmacological or clinical response to the administration of
a drug combination different from that anticipated from the known effects of the two agents
when given alone.
There are several incidence that a patient may suffer from more than one disease at a
time. Many patients especially the elderly are treated continuously with more than one drug
for chronic diseases such as hypertension, heartfailure, osteoarthritis 1.The more drugs people
take,the more likely they are to have problems caused by one drug interfering with another
drug or disease. Older people particularly have problems with drug response. Their liver and
kidneys function less effectively, so drugs that are broken down by the liver or excreted by
the kidney tend to accumulate, thus potentially causing problems, During the concomitant
usage of multiple drugs, there is possibility of occurrence of drug drug interactions. Even
these interactions may be so severe as to cause mortality. By the survey it has concluded that
incidence of drug drug interactions may be very high in case of hospitalised patients2,3,4.
           The frequency of adverse drug reactions increases disproportionately with an increase
in the number of drugs given to patients5. Drug drug interactions are well recognized causes
of adverse drug effects. Drug drug interactions are a particularly important type of adverse
drug event because they are often predictable based on previous reports, clinical studies, and
an understanding of pharmacological principles7.
           Numerous studies have demonstrated that many patients receive multiple drug therapy
with  agents  of  recognized  potential  for  interaction.  As  the  number  of  drugs  in  a  patient
receives multiple drug therapeutic regimen increases, the greater is the risk of occurrence of a
drug interaction. The growing use of pharmacological agents means that drug interaction are
of increasing interest for public health. Monitoring of potential drug interaction may improve
the quality of drug prescribing and dispensing and it might form a basis for education focus
on appropriate prescribing an important duty and responsibility of pharmacist is to minimize
their effect if they occur.9
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The knowledge of drug interactions may allow early recognition and prevention of
adverse consequences. The most comprehensive understanding of clinically important drug
interactions  can  be  achieved  by  combining  the  knowledge  of  mechanisms  with  the
recognition of high risk patients and the identification of drugs with a narrow therapeutic
index. It is essential for all members in the health profession to be aware about potential drug
drug interactions and strategies to overcome them. A concerted effort is required to minimise
the problems of drug interactions. Each molecule even at therapeutic dose may have certain
side effects, but when given in combination drug might augment or diminish the benefit of
the other drugs. Hence ,it is important to discuss about the occurrence and management of
potential drug drug interactions and bring awareness amongst the health care professional.
Pharmacist being in a competent world can play an active role in the assessment as well as
prevention of drug drug interactions4.
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Drug  interaction  is the pharmacological or clinical response to the administration
or  co –exposure of  a  drug  with another substance that modifies the patients response to the
drug. It is reported that 20-30% of all adverse reactions to drugs are caused by interactions
between drugs10 . This incidence increases among the elderly and patients who take two or
more medications.
There are several incidences that a patient may suffer from more than one disease at a
time,  so  it  is  necessary  to  treat  all  these  ailments  simultaneously.  Hence  it  requires  to
administer more than one drug at the same time. During the concomitant usage of multiple
drugs, there is every possibility of occurrence of drug drug interactions and these interactions
may be sometimes so severe to cause mortality11,12 
Not all drug drug interactions are similar in nature sometimes when two drugs interact
, the overall effect of one or both of the drugs may be greater or lesser than desired, e.g.
Aspirin in low doses used to prevent platelet aggregation and to prevent clot formation when
administered along with oral anticoagulants,  aspirin will enhance anticoagulant activity of
these but this interaction sometimes leads to dangerous hemarrhoegic condition by causing
excessive bleeding.
A drug  interaction  refers  to  the  possibility  that  one  drug  may  alter  intensity  of
pharmacological  effects  of  another  drug when given concurrently.  The net  result  may be
enhanced or diminished effects of one or both of the drugs or the appearance of a new effects
that  is  not  seen  with  either  of  the  drug  alone11 .The  most  important  adverse  drug  drug
interactions occur with drugs that have serious toxicity and a low therapeutic index ,such that
relatively  small  changes  in  drug  level  can  have  significant  adverse  consequences.
Additionally drug drug interactions can be clinically important if the disease being controlled
with the drug is serious or potentially fatal if under treated12.
Drug interactions are  frequent in medical practice,  and their incidence increases
with  the  number  of  concurrent  medications.  The  elderly  are  particularly  prone  to  drug
interactions,as they are more likely to take more drugs .In addition to age ,other risk factors
for drug  interactions are malnutrition, malabsorption ,chronic liver disease (including liver
metastasis),and impaired renal function39,40,41. Pharmacogenetic characteristics of individual
patients may also contribute to different drug effects.
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            Drug combinations with potential to interact are common in medical practice,although
their frequency in general medicine has been variable , depending on the patient population,
study design, and the screening methods used to identify interactions.  In  general  medical
wards, the rate of potential drug interactions has been approximately 60%. Studies conducted
in emergency departments found frequencies of potential drug interactions in the range of
16% and 47%37. Ambulatory patients with variable clinical conditions who were screened for
potential drug interactions by their family physician were found to be exposed to a potential
drug interactions by their family physician were found to be exposed to a drug interaction in
almost 70% of cases. 
Drug interaction is a situation in which a substance affects the activity of drug, when
both are  administered  together.This  action  can  be  synergistic  or  antagonistic  (Synergistic
means the drugs effect is increased. Antagonistic means the drug effect is decreased) or a new
effect can be produced that neither produces on its own. Typically interactions between drugs
come to mind.(drug drug interaction).
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If a patient is taking two drugs and one of them increases the effect of the other. It is
possible that an overdose may occur. The interaction of the two drugs may also increase the
risk of that side effects will occur.On the other hand , if the action of a drug is reduced it may
cease to have any therapeautic use because of under dosage.
Example; The use of codeine with paracetamol to increase its analgesic effect.
FACTORS AFFECTING DRUG INTERACTIONS
• Old age;
Age may affect  the  interaction  of  drugs.  For  example  ,  liver  metabolisam,kidney
function, nerve transmission or the functioning of bone marrow all decrease with age.  In
addition in old age there is a sensory decrease that increase the chances of errors being made
in the  administration of drugs.
• Polypharmacy;
The more drugs a  patient  takes  the more likely it  will  be that  some of them will
interact.
• Genetic factors; 
Genes  synthesize  enzymes  that  metabolize  drugs.  Some  races  have  genotypic
variations that could decrease or increase the activity of these enzymes. The consequence of
this would, on occasions, be a greater predisposition towards drug interactions and therefore a
greater predisposition for adverse affects to occur. This is seen in genotype variations in the
isoenzymes of cytochrome p450.
• Hepatic or renal diseases;
The blood concentrations of drugs that are metabolized in the liver or eliminated by
the kidneys may be altered if either of these organs is not functioning correctly. If this is the
case an increase in blood concentration is normally seen.
Serious diseases that could worsen if the dose of the medicine is reduced.
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• Drug dependent factors;
Narrow therapeutic index;
Where the difference between the effective dose and the toxic dose is small. The drug
digoxin is an example of this type of drug.
Steep dose  response curve;  Small  changes in  the dosage of  a  drug produce large
changes in the drugs concentration in the patients blood plasma.
Saturable hepatic metabolisam; In addition to dose effects the capacity to metabolize
the drug is greatly decreased .
CLASSIFICATION OF DRUG DRUG INTERACTION ;
There are a number of mechanisms by which drugs interact with each other and most
of them can be divided into two general categories.
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PHARMACOKINETIC AND PHARMACODYNAMIC INTERACTIONS.
With pharmacokinetic drug interactions, one drug affects the absorption , distribution,
metabolisam, or excretion of another. When pharmacodynamic drug interactions occur’ two
drugs have additive/synergistic or  antagonistic pharmacologic effects.  Either  type of  drug
interaction can result in adverse effects in some individuals.
PHARMACOKINETIC DRUG DRUG INTERACTIONS
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Drug  may  be  interacting  at  any  point  during  their  absorption,  distribution
,metabolisam or excretion ,the result may be an increase or decrease in the concentration of
either drug at the site of action. As individuals vary in their rate of  disposition of  any given
drug ,the magnitude of an interaction that alters pharmacokinetic parameters is not always
predictable, but it can be vary siginificantly12.
DRUG ABSORPTION INTERACTION
Most of the drugs are given orally for absorption through the mucous membrane of
the GIT, and the majority of  interaction that go on  within  the gut result in reduced rather
than the increased absorption19.
a. Effects of changes in gastro intestinal pH
The passage of drugs through mucous membrane by simple passive diffusion depends
upon the extend to which they exist in non ionised lipid soluble form. Absorption is therefore
governed by the pka of a drug, its lipid solubilit ,pH of the contents of the gut and various
other parameters relating to the pharmaceutical formulation of the drug19.
Rises in pH due to proton pump inhibitors and H2 receptor antagonists, can markedly
reduce the absorption of  ketoconazole19.
b. Adsorption, chelation  and other complexing  mechanisms
Activated charcoal and antacids can adsorb a large number of drugs.
Eg.Cholestyramine  form  complexes  with  digoxin,  levothyroxine,  warfarin  and  results  in
reduced absorption of these drugs. 
Antacids reduce the absorption of drugs like ketoconazole, penicillamine, quinolones
and tetracyclines by forming less soluble complexes.
c. Effects of changes in gastrointestinal motility
Propantheline delays gastric emptying and reduces paracetamol absorption, where as
metoclopramide  has  the  opposite  effect.  Drugs  with  anti  muscarinic  effects  decrease  the
motility  of  the  gut,  thus  the  tricyclic  antidepressants  can  increase  the  absorption  of
dicoumarol, probably because the time available for dissolution and absorption but in the case
ULTRA COLLEGE OF PHARMACY, MADURAI  PAGE  9
             
of levodopa , they may reduce the absorption probably because the exposure time to intestinal
mucosal metabolisam is increased19.
d. Induction or inhibition of drug transporter proteins.
The oral bioavailability of some drugs is limited by the action of drug transporter
proteins , which eject drugs that have diffused across the gut lining back into the gut.
Digoxin is a substrate of  P-glycoprotein, and drugs that induces this protein, such as
rifampicin,may reduce the bioavailability of digoxin19.
e .Mal- absorption caused by drugs.
Neomycin causes a malabsorption syndrome, similar to that seen with non-tropical
sprue.  The effect  is  to impair the absorption of a number of drugs including digoxin and
methotrexate19.
DRUG  DISTRIBUTION  INTERACTIONS.
Drug distribution to the target site after absorption is  determined largely by blood
flow to the area and the binding properties of the drug to plasma proteins. Drugs can bind to
several  blood components ,  such as albumin, alpha 1-acid glycoprotein, lipoproteins  and
immunoglobulin. The  unbound drug is regarded as the biologically active fraction because it
is able to exert its effect on the pharmacological target with in tissues. Therefore, binding to
blood components limits the activity of the drug19.
The mechanism by which drug interactions alter drug distribution include
(1) Competition for plasma protein binding site.
      Although  competition  for  plasma  protein  binding  can  increase  the  free
concentration  of  drug  after  displacement  in  to  plasma,  the  increase  tends  to  be
temporary owing to a compensatory increase in drug disposition.
(2) Displacement of first drug from tissue binding sites.
     The importance of displacement of drug from protein binding site has probably
been  over  emphasized,  only  few  drugs  are  known  to  cause  clinically  important
interactions by this mechanisms.(e.g. oral anti coagulants, sulfonylureas)
(3) Induction or inhibition of drug transport proteins
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       It is increasingly being recognised that distribution of drugs into the brain, some
other organs such as testes, is limited by the action of drug transporter proteins such as
P-glycoprotein . These proteins actively transport drugs out of cells when they have
passively diffused in. Drugs that are inhibitors of these transporters could therefore
increase  the uptake of drug substrates into the brain,  which could either  increase
adverse CNS effects, or be beneficial41.
DRUG METABOLISAM (biotransformation) INTERACTIONS
Drug metabolisam takes place in the serum, the kidneys, the skin and the intestines,
but the greatest proportion is carried out by enzymes that are found in the membranes of the
endoplasmic reticulum of the liver cells.  The majority of phase 1 oxidation reactions are
carried out by cytochrome450.
a) Changes in first pass metabolisam.
i) Changes in blood flow through liver.
A number of highly lipid soluble drugs undergo substantial biotransformation. Drugs
first pass through the gut wall and liver and some drugs have a marked effect on the extend of
first pass metabolism by altering the blood flow through the liver.
Eg;  increase  in  bioavailability  of  high  extraction  beta  blockers  with  hyralazine  possibly
caused by altered hepatic blood flow, or altered metabolism19.
ii )  inhibition or induction of first pass metabolism;
The  gut  wall  contains  metabolising  enzymes,  principally  the  cytochrome  P450
isoenzymes  .Drugs  which  inhibit  or  induce  this  enzyme  may  increase  or  decrease  the
bioavailability of  some other drugs42.
b) Enzyme induction;
Some drugs called “enzyme inducers” are capable of increasing the activity of drug
metabolizing enzymes, and increase the  metabolism of  other drugs and results in reduced
drug effect. So, larger doses are needed to maintain the same therapeutic effect. The enzyme
induction interactions are delayed in onset and slow to resolve .Examples of enzyme inducers
include barbiturates, phenytoin, carbamazepine, griseofulvin, phenytoin, primidone, rifabutin,
and  rifampin 
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If drug A is metabolized by cytochrome p450 enzyme and drug B induces or increases
the enzymes activity,  then blood plasma concentrations  of drug A will  quickly fall  as  its
inactivation will  takes  place  more  rapidly.  As  a  result,  enzymatic  induction  will  cause  a
increase in the drugs effects.
Some drugs, such as ritonavir depending on the situation may act as either an enzyme
inhibitor or an enzyme inducer. Drugs metabolized by CYP3A4 or CYP2C9  are particularly
susceptible to enzyme induction . In some cases, especially for drugs that undergo extensive
first  pass  metabolism  by  CYP3A4  in  the  gut  wall  and  liver,  the  reduction  in  serum
concentrations of the object drug can be profound.
Enzyme induction resulting in toxic metabolites;
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Some drugs are converted to toxic metabolites by drug metabolizing enzymes. For
example, the analgesic acetaminophen is converted primarily to non toxic metabolite, but a
small amount is converted to a metabolite, but a small amount is converted to a cytotoxic
metabolite. Enzyme inducers can increase the formation of the toxic metabolites and increase
the risk of hepatotoxicity as well as damage to other organs.
c) Enzyme inhibition;
It is more common than enzyme induction . This results in the reduced metabolism of
an affected drug, so that it  may begin to accumulate in the body .Enzyme inhibition can
occure within 2-3 days, resulting in rapid development of toxicity. The metabolic pathway
that is most commonly inhibited is phase 1 oxidation by the cytochrome p450 isoenzyme.
Examples  of  enzyme  inhibitors  include  cimetidine,  fluvoxamine,  fluoroquinolones
(ciprofloxacin, enoxacin)19.
Enzyme inhibition increasing risk of toxicity;
Most  drugs  are  metabolized to  inactive  or  less  active  metabolites  by enzymes  in
theliver and intestine. Inhibition of this metabolism can increase the effect of the object drug.
If the increase in effect is large enough, drug toxicity may result. This is one of the most
common mechanisms by which clinically important drug interactions occur. Since only a few
different  cytochrome  P450  isozyme  are  involved  in  drug  metabolism  and  competition
between two drugs for these isozymes will occasionally occur. This competition may result in
alteration with the metabolism of one or both the drugs.
For example, inhibitors of CYPIA2 can increase the risk of toxicity from clozapine or
theophylline.  Inhibitors  of  CYPZC9  can  increase  the  risk  of  toxicity  from  phenytoin,
tolbutamide, and  oral anticoagulants such as warfarin. Inhibitors of CYP3A4 can increase
the risk of toxicity from many drugs including carbamazepine, cisapride, cyclosporine, ergot
alkaloids,  lovastatin,  pimozide,  protease  inhibitors,  rifabutin,  simvastatin,  tacrolimus  and
vinca alkaloids.
Enzyme inhibitors resulting in reduced drug effect:
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 A small number of drugs are not active in the form administered to patients. These
drugs are known as prodrugs and require activation by enzymes in the body before they can
produce their effect. Inhibition of the metabolism of these prodrugs may reduce the amount
of active drug formed, and decrease or  eliminate the therapeutic effect.  For example,  the
analgesic and toxic effects of codeine appeared to result from its conversion to morphine by 
CYPZD6. Thus CYPZD6 inhibitors can impair the therapeutic effect of codeine. CYPZD6
inhibitors may similarly effect the analgesic effect of hydrocodone.
d) Genetic factors in drug metabolism;
           Depending on the genetic polymorphism of cytochrome P450 isoenzymes, individuals
have varying ability to metabolize certain drugs.
Individuals fall in ‘poor or slow metabolisers’ or ‘fast or extensive metabolisers’19.
e) Cytochrome P450 isoenzymes and predicting drug interaction;.
By doing invitro tests with human liver enzymes, it is often possible to explain why
and  how some drugs interact.
DRUG ELIMINATION/EXCRETION INTERACTIONS;
With the exception of the inhalational anaesthetics, most drugs are excreted either in
the bile or in the urine. Interference by drugs with renal tubular fluid pH, with active transport
systems and with blood flow to the kidneys can alter the excretion of other drugs19.
a) Changes in urinary pH;
Passive reabsorption of drugs depends upon the extend to which the drugs exists in the
non ionised lipid soluble form, which in turn depends on its pKa of the urine. Thus at high pH
values (alkaline),weakly acidic drugs (pKa 3 to 7.5) largely exist as ionized lipid insoluble
molecules, which are unable to diffuse into the tuble cells and will therefore remain in the
urine and be removed from the body. The converse will be true for weak bases with pKa
values of 7.5 to 10.5. Thus, pH changes that increase the amount in the ionized form (alkaline
urine for acidic drugs, acid urine for basic drugs) increase the loss of drug, where as moving
the pH in the opposite direction will increase their retention.
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For example,  probenecid can increase the serum levels of cephalosporins,  dapsone,
methotrxate, penicillins, quinolones. Salicylates and some other NSAIDs can increase serum
level of methotrexate resulting in the possibility of serious toxicity.
b) Changes in active renal tubular excretion;
Drugs that use the same active transport systems in the renal tubules can compete with
one  another  for  excretion.  Eg;  probenecid  reduces  the  excretion  of  penicillin  and  other
drugs19.
c) Changes in urinary blood flow;
The flow of blood through the kidney is partially controlled by the production of renal
vasodialatory prostaglandins. If  the synthesis of these prostaglandins is inhibited,the renal
excretion of some drugs may be reduced. Eg;  Increase in serum lithium seen with some
NSAIDs19.
d) Biliary excretion and entero- hepatic shunt;
i) Enterohepatic recirculation;
A number of drugs are excreted in the bile, either unchanged or conjugated (Eg; as the
glucuronide) to make them more water soluble. Some of the conjugates are metabolized to
the  parent  compound  by  the  gut  flora  and  are  then  reabsorbed.  This  recycling  process
prolongs the stay of the drug within the body,  but if  the gut flora are diminished by the
presence of an anti- bacterial , the drug is not recycled and is lost more quickly. Eg;  The
failure of oral contraceptives with concurrent use of penicillins or tetracyclines41.
ii) Drug transporters;
Numerous drug transporter proteins (both from the ABC family and SLC family) are
involved in the hepatic excretion and secretion of drugs into the bile. The bile salt export
pump (ABCB 11) is  known to be inhibited by a variety of  drugs  including ciclosporins,
glibenclamide and bosentan. Inhibition of this pump may increase the risk of cholestasis.
ABCB1 has a role in the renal elimination of substances by active secretion into the
urine. It is localized at the brush- border membrane of the proximal renal tubule ( luminal
side), where it pumps drug molecules into the tubular filtrate. ABCB1 inhibition results in an
increase in the systemic exposure and tissue distribution of drugs that are ABCB1 substrates,
whereas the induction of ABCB1 leads to a decrease in systemic exposure. ABCB1 that is
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expressed in the liver also has a role in the elimination of unchanged drugs and metabolites.
Localized  in  the  canalicular  membrane  of  hepatocytes,  the  efflux  protein  pumps  drug
molecules into the bile, where they can be reabsorbed from the intestine or eliminated in the
faeces.
The directional movement of drugs across organs such as the gastrointestinal tract,
liver  and  kidneys  requires  drug  uptake  transporters  as  well  as  efflux  transporters.  For
example,  organic  anion  transporters  (OATs)  and organic  anion-  transporting polypeptides
(OATPs) are expressed in organg of importance to drug disposition can mediate and response,
such   as  the  CNS,  liver  and  intestine,  and  can  mediate  the  cellular  uptake  of  several
structurally  diverse  compounds.  Typically,  larger  and  more  lipophilic  organic  anions  are
transported in the liver by OATPs, whereas small hydrophilic organic anions are extracted by
OATs, which are highly expressed on the  basolateral side of renal proximal tubules.
e) Changes in renal secretion;
For  some  drugs  ,  active  secretion  into  the  renal  tubules  is  an  important  route  of
elimination. For example, digoxin is eliminated primarily through renal excretion, and drugs
such as amiodarone, clarithromycin, itraconazole, propafenone, and quinidine can inhibit this
process leading to digoxin toxicity may result when administered concomitantly40.
PHARMACODYNAMIC DRUG INTERACTIONS;
Pharmacodynamic interactions can be categorized broadly as synergistic (when the
effect of two drugs is greater than the sum of their individual effects); antagonistic (drugs
with opposing pharmacologic effects); additive (when the effect of two drugs is merely the
sum of the effects of each); and sequence –dependent( when the order in which two drugs are
given governs their effects.
The two drugs may or may not act on the same receptors to produce such effects10.
1. Additive or synergistic interactions;
When  two  or  more  drugs  with  similar  pharmacodynamic  effects  are  given,  the
additive  effects  may  result  in  excessive  response  and  toxicity.  Examples  include
combinations of drugs that prolong the QT interval resulting in ventricular arrhythmias, and
combining drugs with hyperkalemic effects resulting in hyperkalemia. Eg . Many diuretics
lower plasma K+ concentration and there by enchances toxic actions of cardiac glycosides
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(digitalis) and predispose to glycoside toxicity with antiarrhytmic drugs that prolong cardiac
action  potential  and  Monoamine oxidase  inhibitors  increase  the  amount  of  noradrenaline
stored in noradrenergic nerve terminals and there by interact dangerously with drugs, such as
“ Ephedrine or tyramine”, that work by releasing stored nor adrenaline41.
2.   Antagonistic or opposing interactions;
Drugs with opposing pharmacodynamic effects may reduce the response of one or
both drugs. For example, NSAIDs oppose the  antihypertensive effect of ACE inhibitors or
loop diuretics; glucocorticoids oppose the  blood glucose lowering effect  of antidiabetics;
megestrol  oppose  the  antineoplastic  effect  of  antineoplastics;  vitamin  K  oppose  the
anticoagulant effect of anticoagulants19.
3 Drug or neurotransmitter uptake interaction;
A number of drugs with actions that occur at adrenergic neurons can be prevented
from reaching those sites of action by the presence of other drugs. The tricylic antidepressants
prevent  the re  uptake  of  noradrenaline  into peripheral  adrenergic  neurons.  Thus,  patients
taking tricyclines and given parenteral noradrenaline have a markedly increased  response
(hypertension, tachycardia)19.
PHARMACEUTICAL INTERACTIONS;
Pharmaceutical interactions occur when two compounds interact because of they are
incompatible either physically or chemically.
Although dramatic advances have been made in the study of drug drug interaction
mechanisms over the past few decades, there is still much to learn about these. Thus, many of
the mechanism concepts useful today will be refined in the future, yielding a picture closer to
the truth, it also should be kept in mind that for some drug drug interactions there may be
more than one mechanism occurring simultaneously.
In  case of  reversible inhibition the enzyme inhibited by the first  drug may not  be
recognised by the concomitantly administered drug which is the substrates of the inhibited
enzyme and it may take few days for recovery. Eg; cemetidine and macrolide antimicrobials
directly  form  complex  with  heme  moiety  of  CYP  isoenzymes.  Where  as  irreversible
inhibition leads to inactivation of the enzyme system,also known as mechanism based or
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suicide inhibition. Eg.Ethinyiestradiol, gestodene and levonorgesterol are reported to cause
mechanism based inhibition42
It has long been established  that elderly patients use more medicines than younger age
groups and  thus  have  a  greater  risk  of  experiencing   a  drug drug interaction.  In  elderly
patients, the reserve capacity of many organs may be considerably reduced, and because of
this erosion, there is narrowing of the safety margin between the therapeutic and toxic dose of
drugs.
Pharmacokinetics effects of drugs may be increased or decreased in the elderly patient.
Age related differences in kinetics in elderly is primarily due to diminished renal function,
altered proportion of body fat and water , reduced cardiac output and some degree of altered
hepatic metabolism. 
Pharmacodynamic  interactions  are  also  influenced  by  age.  The  elderly  show  an
increased response to ACE inhibitors, they show an increased responsiveness to propanolol.
The inotropic effect of Theophylline is increased with age, but its bronchodilator effect is
reduced. The anticoagulant effect of warfarin is increased in elderly patients due to greater
fragility of the hepatic synthesis of clotting factors.
ULTRA COLLEGE OF PHARMACY, MADURAI  PAGE  18
             
Phenothiazine,  diuretics,  antihypertensives,  beta  adrenoreceptor  antagonists,
antidepressants, NSAIDs, benzodiazepines and lignocaine are all examples of drugs that are
likely to produce enhanced pharmacological or toxic effects in the elderly
Drug  drug interactions can have potentially life-threatening consequences in older 
adults,who often take several drugs at once for multiple diseases. Elderly patients are more 
susceptible to drug interactions than younger patients because of age-related physiologic 
changes and the sheer number of drugs they are taking
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FitaRahmavati&etal.(2007)Conducted a study in a private hospital at Yogyakarta in
Indonesia from july until December 2007. The finding of this study showed that the mean
number of medication per cases per day was 5.8 + 2.1 (+SD) Of the 100 cases ,65%cases had
experienced potential DDIs range from 1to 17 . Of total 204 DDIs incidences, 25% were of
significance level 1 and 39% of significance level 2. Twelve cases (12%) have more than 4
incidences of DDIs. Our study showed that the number of potential DDIs increased as the
number  of  medications  used  per  day  increased.  Geriatric  patients  taking  nine  or  more
medication tended to have more DDIs (6.8+5.5) in comparison to those with one to two
medications with no DDIs. The result of liner regression analysis indicated that number of
medication used per day have positive relationship on number of DDIs (p =0.000). Incidence
of DDIs in geriatric patients was frequent and pharmacist can play a critical role in managing
medication  therapy  of  patients  with  collaboration  with  other  professional  health  care  to
prevent adverse drug reactions 38.
Mr.Hemendragautam (2006)in  may  did  a  study  on  drug  drug   interactions,  in
Medicine Department, K.L.E.S Hospital and medical Research center, Belgaum, Karnataka.
In 85 patients 207 potential drug drug interactions were found out in his study. In his study,
the most common drug classes involved in DDIs were anti hypertensives and antibiotics .
There was a uniform increase in the percentage of DDIs with an associated increase in the
number of  drugs.20
Daniel C.Malone et al (2005)  suggested the prevalence of  25 clinically important
potential  drug  drug  interactions  DDIs  in  a  population  represented  by  the  drug  claims
databases of a pharmacy  benefit management company PBM was studied . The number of
DDIs ranged from 37 for pimozide and azole anti fungal to 127,684 for warfarin and a non
steroidalanti  inflammatory drugs.  The  highest  prevalence  and  highest  case  exposure  rate
occurred  with the warfarin NSAID combination. The combination with the lowest overall
prevalence differs  from the combination with the lowest  case-  exposure rate.  Number of
cases, prevalence, and case exposure rates for both sexes generally increased with age. An
estimated 374,000 participants were exposed to a clinically important DDI during a 25 month
period. Between 20% and 46% of prescription drug claims were reversed for a medication
with a drug interaction when a warning about the interaction was sent to the pharmacy.21
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Robert A.Hamilton& et al, studied Frequency of Hospitalization after Exposure to
known drug drug interactions in a Medicaid population. A matched  pair case control analysis
of  Medicaid claims was performed to determine the risk of hospitalization associated with
drug drug interactions. Patients were hospitalized and controls were not. They were randomly
matched  based  on  contemporaneous  eligibility  for  Medicaid  benefits.  Odds  ratios  for
hospitalization in patients exposed to one of the interacting agents. When confidence intervals
did not overlap, the odds ratio was considered to be significantly increased. Odds ratios were
significantly increased for many interacting drug pairs; and were associated with commonly
recognized  interactions  achieved  significance  only  with  theophylline  .  In  the  Medicaid
population,  exposure  to  a  number  of  drug  drug  interactions  was  associated  with  a
significantly increased risk of hospitalization.22
L. Bjermm, J. Sogaard, J. Halls, analyzed the occurrence of multiple drug use (poly
pharmacy, pp) in the population and the identify individuals particularly prone to PP.On  a
random day, 8.3% of the populations were exposed to minor PP and 1.2% to major PP. The
prevalence of  PP increased with age, and from the age of 70 years, two thirds of all drug
users were PP users. Drug use was 50% more prevalent among women than men, but over the
age  of  70,  the  sexes  did  not  differ  in  the  prevalence  of  major  PP.  Many different  drug
combinations were found, and among major PP users (n = 5443), two thirds had their own
unique regimen, different from all other drug users. Cardiovascular drugs and analgesics were
often involved in PP among the elderly,  while asthma drugs,  psychotropic drugs and anti
ulcer drugs were predominant among individuals exposed to PP. The odds ratio (OR) for
major PP was substantially increased for individuals treated for cardiovascular diseases(OR,
4.5),  anaemia  (OR  ,4.1)  and  respiratory  diseases  (OR,  3.6)  .  Document  the  degree  of
polypharmacy,  the frequency diseases  of  adverse drug related  events  (  ADEs)  leading to
emergency physicians, and the frequency of  potential adverse drug interactions (PADIs) in
medication regiments of elderly patients in the ED.23
Franklin E. May ,& et al  (2004)  studied effect of multiple drug administration on
drug reactions in 10,518 patients hospitalizes on a general medical service during a five year
period.  Drug  groups,  including  analgesic,  antacid,  anti  arrhythmic,  antimicrobial,
anticoagulants, antihypertensive, anti inflammatory, diuretic, and sedative tranquilizer drugs,
were selected for study. The average number of adverse drug reactions for the anticoagulant
and anti hypertensive drug groups was higher(p 0.05) than for all other drugs groups when
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classified by the number of drugs being taken concurrently (i.e, 0 to 5,6 t0 10, etc). The rate
of reaction for anticoagulant and antihypertensive drug groups was higher (p 0.001)than the
rate for other drug groups studied. These data suggest a higher risk of adverse drug reactions
for patients receiving multiple drugs. The increased risk may result from drug interactions.25
Donna M. Fick, RN; &et al (2003) Conducted a study for updating the Beers criteria
for  potentially  Inappropriate  Medication  use  in  Older  Adults.  This  study  identified  48
individual medications or classes of medications to avoid in older adults and their potential
concerns and 20 diseases/ conditions and medications.  Of  these potentially inappropriate
drugs, 66 were considered by the panel to have adverse outcomes of high severity.26
David N. Juurlink& et  al  (2003) determined whether elderly patients admitted to
hospital with specific drug toxicities were likely to have been prescribed an interacting drug
in the week prior to admission. During the 7 year study period, 909 elderly patients receiving
glyburide were admitted with a diagnosis of hypoglycaemia. In the primary analysis , those
patients admitted for hypoglycaemia were more than 6 times as likely to have been treated
with co trimoxazole in the previous week  adjusted  odds ratio , 6.6;95 confidence interval,
4.5 – 9.7. Patients admitted with digoxin toxicity n;1051 were about 12 times more likely to
have been treated with clarithyromycin adjusted odds ratio, 11.7; 95% confidence interval,
7,5 – 18.2 in the previous week, and patients treated with ACE inhitors admitted with a
diagnosis of hyperkalemia n; 523 were about 20 times more likely to have been treated with a
potassium sparing diuretic adjusted odds ratio, 20.3; 95% confidence interval, 13.4- 30.7 in
the  previous  week.  No increased  risk  of  drug  toxicity was  found for  drugs  with  similar
indications but no known interactions amoxicillin, cefuroxime, and indapamide , respectively,
prescription of  contraindicated and interacting  drugs in elderly patients admitted in hospital.
Another study determines the prevalence and predictors of  inappropriate drug prescribing
defined by expert national consensus panel drug utilization review criteria for community
dwelling older people.27
Kenneth E.  Schmader& et  al  (2004)drtermined if  inpatient  or  outpatient  geriatric
evaluation and management, as compared with usual care, reduces adverse drug reactions and
sub optimal prescribing in frail  elderly patients. For serious adverse drug reactions,  there
were no inpatient geriatric unit effects during the   inpatient or outpatient follow up periods.
Outpatient geriatric clinic care resulted in a 35% reduction in the of a serious adverse drug
reaction compared with usual care ( adjusted relative risk =0.65; 95% confidence interval ;
0.45 to 0.93). Inpatient geriatric unit care reduced unnecessary and inappropriate drug use
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and under use significantly during the inpatient period (p o0.05). Outpatient geriatric clinic
care reduced the number of  conditions with omitted drugs significantly during the outpatient
period ( p 0.05) .Another study estimates the incidence of serious and fatal  adverse drug
reactions( ADR) in hospital patients.29
Mark H.  Beers,  & et  al  determined  how often  emergency department  physicians
prescribe medications that can adversely interact with other medications that their  patients
are already taking,  which patients  are at  hihhest  risk for  potential  adverse reactions,  and
which medications most frequently lead to adverse interactions. In this study evaluated 424
randomly selected visits to a hospital emergency department made by 186 persons over age
65 and 238 younger adults; all of the subjects were discharged without hospital admission.
Forty seven percent of visits led to added medication, and in 10% of the visits in which at
least one medication was added, a new medication added a potential adverse interaction. The
interactions  were  dererminded  by  a  computer   program,  were  reviewed   using  explicit
criteria,  and  were  excluded  if  of  uncertain  or  trivial  clinical  significance,  rare,  or  not
established at presentation was the best predictor of whether a potential interaction would be
introduced.30
VerenaBergk, et al,(2004) Estimated the risk associated with drug interaction in a
larger population when not only the severity of possible clinical events but also measures of
their prevention( manageability, modulating factors are  considered. More then 52%of  the
patients received combination therapy. Interaction information was available in a standard
sorce( DRYGDEX; Thomas MICROMEDEX, Greenwood Village, Colo) for only 1029 of all
13,672 individual prescribed drug pairs. Of the dwg pairs, 881 (6.45%) were identified as
interacting. Of these 881 interactions,  132(15%) were of  major  severity but 101 of   132
(76.5%)  were  considered  manageable  .  Only  31(23.5%)  of  132  major  interactions  (ie,
31/881[3.5% of all interacting pairs]) offered on management options and should thus be
avoided.31
Jerry H. & et  al assessed the incidence and preventability of adverse drug events
among older persons in the ambulatory clinical setting. There were 1523 identified adverse
drug events, of which 27.6%(421) were considered preventable. The overall rate of  adverse
drug events was 50.1 per 1000 person  - years, Of  the adverse drug events, 578(38.0%)
were categorized as serious,life threating, or fatal; 244 (42.2%) of these more severe events
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were deemed preventable compared with 277 (18.2%) of the 945 significant adverse drug
events. Errors associated with preventable adverse drug events occurred most often at the
stages  of  prescribing  (n=  89,21.1%)  also  were  common.  Cardiovascular  medications
(22.4%),  followed  by  diuretics  (22.1%),  non  opiod  analgesics  (15.4%),  hypoglycaemic
(10.9%),  and  anticoagulants  (10.02%)  were  the  most  common  medication  categories
associated with preventable adverse drug events. Electrolyte/renal (26.6%), gastrointestinal
tract  (21.1%),  hemorrhagic  (15.9%),  metabolic/   endocrine (13.8%) and neuropsychiatry
(8.6%) events were the most common types of preventable adverse drug events.32
David W. Bates & et al ( 1995) assessed incidence and preventability of adverse drug
events (ADEs) and potential ADEs. To analyze preventable events to  potential ADEs were
identified.  Extrapolated event rates were 6.5 ADEs and 5.5 potential  ADEs per 100 non
obstetrical admissions, for mean numbers per hospital per year of approximately 1900 ADEs
and  1600  potential  ADEs.  Of  all  ADEs,  1%  was  fatal  (none  preventable),  12%  life
threatening,  30%  serious,  and  57%  significant.  Twenty  eight  percent  were  judged
preventable.  Of the life threatening and serious ADEs, 42% were preventable,  compared
with 18% of significant ADEs. Error resulting in preventable  ADEs occurred most often at
the stages of ordering (56%) and administration (34%); transcription (6%) and dispensing
error (4%) were less common. Error were much more likely to be intercepted if  the error
occurred  earlier  in  the process;  48% at  the  ordering stage  vs.  0% at  the  administration
stage.33
Richard Harrison & et al  from old age psychiatry, Castleside offices, Care of the
Health  of the Elderly, Newcastle General Hospital, Westgate Road, Newcastle conducted a
cross sectional survey of patient drug prescriptions on two elderly psychiatric wards was
carried out to estimate the potential of drug drug interactions. Two standardised databases,
British  National  Formulary (BNF;  British  Medical  Association  &  Royal  pharmaceutical
society of  Great  Britain,  2007) and upto data (www. Uptodate.com),  were  employed.  A
majority  (96%)  of  drug  prescriptions  in  their  study  could  potentially  cause  drug  drug
interactions.  Most patients were on multiple drugs ( on average eight drugs per patient).
There was poor concordance between the two databases; BNF picked up fewer cases of
potential drug drug interactions than  upto date (43 v152 instances) and they also estimated
the potential for hazardousness differently.
MaysaaMahmood,  Daniel  C.Malone&  et  al  did  a  retrospective,  cross  sectional
database analysis of pharmacy  records to assess the prevalence of  25 clinically important
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(DDIs) in the ambulatory care clinics of the Department of Veterans Affairs medical centers
(VAMCs).  The 25 DDIs were categorized into four main  categories on the basis of the
therapeutic classification of the medications involved in the drug pairs. The study population
included 2,795,345 patients who filled prescriptions for medications involved in potential
DDIs across 128 VAMCs. The highest DDI exposure rate was 129.2 per 1,000 recipients of
monoamine  oxidase  inhibitors  (MAOIs)  that  occurred  with  combinations  of  selective
serotonin reuptake inhibitors (SSRIs). The lowest DDI exposure rate was 0.01 per 1,000
warfarin recipients who had the warfarin and sulfinpyrazone combination. The analysis of
pharmacy records  of  veterans  who  filled  prescriptions  at  the  outpatient  settings  within
VAMC found an overall rate of 2.15% for potential DDIs. Case exposure rates were greatest
for veterans receiving SSRIs and MAOIs, ganciclovir and zidovudine, anticoagulants and
thyroid hormones, and warfarin and nonsteroidal anti-inflammatory drugs.35
Daniel  C.  Malone,  David  S.Hutchins&  et  al.  Conducted  a  retrospective  cross
sectional analysis of pharmaceutical claims for almost 46 million participants in a PBM to
determine the frequency of 25 DDIs previously identified as clinically important. A DDI was
counted when drugs in potentially interacting combinations were dispensed within 30 days
of each other during a 25 month period between April 2000 and June 2002. The number of
DDIs ranged from 37 for pimozide and an azole antifungal to 127,684 for warfarin and a
nonsteroidal anti-inflammatory drug (NSAID). The highest prevalence (278.56 per 100,000
persons) and highest case exposure rate (242.7 per 1,000 warfarin recipients ) occurred with
the warfarin  - NSAID combination. The combination with the lowest overall prevalence
( cyclosporine and a rifamycin, 0.10/100,000) differed from the combination with the lowest
case  exposure  rate  (  pimozide  and  an  azole   antifungal  recipients).  Number  of  cases,
prevalence,  and  case  exposure  rates  for  both  sexes  generally  increased  with  age.  An
estimated 374,000 plan participants were exposed to a clinically important  DDI during a 25
month period. Between 20% and 46% of prescription drug claims were reversed (cancelled)
for a medication with a drug interaction when a warning about the interaction was sent to the
pharmacy. Analysis of prescription claims data from a major PBM found that 374’000 of 46
million plan participants had been exposed to a potential DDI of clinical importance.36
IK Bjorkman, J Fastbom, IK Schmidt, and CB Bernsten conducted study to detect
the frequency of potential drug drug interactions (DDIs) in an outpatient group of elderly
people in 6 Europen countries, as well as to describe differences among countries. Drug use
data were collected from 1601 elderly persons living in 6 European countries. The study
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population participated in a controlled intervention study over 18 months investigating the
impact of pharmaceutical care. Potential DDIs were studied using a computerized detection
program. Results found that the elderly population used on average 7.0 drugs per person ;
46% had at least 1 drug combination possibly leading to a DDI. On average, there were 0.83
potential DDIs per person . Almost 10% of the potential DDIs were classified to be avoided
according to the Swedish interaction classification system, but nearly one third of them were
to be avoided only for predisposed patients. The risk of subtherapeutic effect as a result of a
potential DDI was as common as the risk of adverse reactions.  Furthermore,  they found
differences in the frequency and type of potential DDIs among the countries.37
Prof. Dr.Joice Mara Cruciol Souza &et al, (2006)  from Brazil conducted a study in
11500 patients for 4  month period and the overall frequency of potential DDI was found to
be 49.7%. The frequency of the potentially major DDI was 3.4%. The rate of  DDI was
significantly associated to in patient’s gender, sex and number of drugs.
Rachel P. Riechelmann. et al., has conducted a study on “ potential Drug Interactions
and Duplicate Prescriptions Among Cancer patients” in princess Margaret Hospital, Toronto,
in 2006. In this study 276 potential drug interactions were identified in 109 patients. The
majority of   drug interactions  were  of  moderate  severity (77%),  and  49% of  them were
supported by levels 1 or 2 scientific evidence. The drug interaction Facts software, version
4.0, was used to identify potential drug interactions and to classify them by level of severity
( major, moderate, or minor) and the strength of scientific evidence for them (using categories
[ 1-5] of decreasing certainity). 
J. Kragstrup a nalyzed, The prevalence of  PP increased with age, and from the age of
70 years,  two thirds of all  drug users were PP users.  Drug use was 50% more prevalent
among women than men, but over the age of 70, the sexes did not differ in the prevalence of
major PP. Many different drug combinations were found, and among major PP users (n =
5443),  two  thirds  had  their  own  unique  regimen,  different  from  all  other  drug  users.
Cardiovascular drugs and analgesics were often involved in PP among the elderly , while
asthma drugs, psychotropic drugs and anti ulcer drugs were predominant among individuals
exposed to PP. The odds ratio  (OR) for major PP was substantially increased for individuals
treated for cardiovascular diseases(OR, 4.5), anaemia (OR ,4.1) and respiratory diseases (OR,
3.6) . Document the degree of polypharmacy, the frequency diseases  of adverse drug related
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events ( ADEs) leading to emergency physicians, and the frequency of  potential adverse drug
interactions (PADIs) in medication regiments of elderly patients in the ED.23
Susan M Wallestdt  et  al.(2006)(Inclusion critera in  this register-based study were
inhabitants in Region Västra Götaland, Sweden, who, at ≥65 years of age and between 1st
July  2006  and  30th June  2010,  filled  their  first  MDD  prescription.  For  each  individual,
prescribed drugs were estimated at three month intervals before and after (maximum 3 years,
respectively) the first date of filling an MDD prescription (index date)
A total of 30,922 individuals matched the inclusion criteria (mean age: 83.2 years;
59.9% female).  There was a temporal  association between the transition to MDD and an
increased number of drugs: 5.4±3.9 and 7.5±3.8 unique drugs three months before and after
the index date, respectively, as well as worse outcomes on several indicators of prescribing
quality. When either data before or after the index date were used, a multi-level regression
analysis predicted the number of drugs at the index date at 5.76 (95% confidence limits: 5.71;
5.80) and 7.15 (7.10; 7.19), respectively, for an average female individual (83.2 years, 10.8
unique diagnoses, 2.4 healthcare contacts/three months). The predicted change in the number
of drugs, from three months before the index date to the index date, was greater when data
before this date was used as compared with data after this date: 0.12 (0.09; 0.14) versus 0.02
(−0.01; 0.05).
After the patients entered the MDD system, they had an increased number of drugs,
more often potentially harmful drug treatment, and fewer changes in drug treatment. These
findings support a causal relationship between such a system and safety concerns as regards
prescribing practices.
CB Bernsten 2002: To detect the frequency of potential drug-drug interactions (DDIs)
in  an outpatient  group of  elderly people  in  6  European countries,  as  well  as  to describe
differences  among  countries.  DATA SOURCES  AND  METHODS:  Drug  use  data  were
collected from 1601 elderly persons living in 6 European countries. The study population
participated in a controlled intervention study over 18 months investigating the impact of
pharmaceutical care. Potential DDIs were studied using a computerized detection program.
RESULTS: The elderly population used on average 7.0 drugs per person; 46% had at least 1
drug combination possibly leading to a DDI. On average, there were 0.83 potential DDIs per
person. Almost 10% of the potential DDIs were classified to be avoided according to the
Swedish interaction classification system, but nearly one-third of them were to be avoided
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only for predisposed patients. The risk of subtherapeutic effect as a result of a potential DDI
was as common as the risk of adverse reactions. Furthermore, we found differences in the
frequency and type of potential DDIs among the countries. CONCLUSIONS: Potential DDIs
are common in elderly people using many drugs and are part of a normal drug regimen. Some
combinations are likely to have negative effects; more attention must be focused on detecting
and monitoring patients using such combinations. As differences in potential DDIs among
countries were found, the reasons for this variability need to 
Paul smith,  2005  studied Computerised drug interaction surveillance systems (CIS)
may be  helpful  in  detecting  clinically  significant  drug  interactions.  Experience  with  CIS
reveals  that  they often yield  alerts  with questionable clinical  significance,  fail  to  provide
relevant information on risk factors for the adverse reaction of the interaction and fail to
detect  all  significant  drug  interactions.  These  problems  highlight  the  importance  of
transparency and selectivity in choosing the drug interactions to be included in CIS. In The
Netherlands, the Working Group on Pharmacotherapy and Drug Information is responsible
for maintenance of the CIS of the Royal Dutch Association for the Advancement of Pharmacy
(KNMP).
Methods:
The  Working  Group  developed  an  evidence-based  procedure  for  structured
assessment of drug-drug interactions and revised all drug interactions in the CIS accordingly.
Results: 
For every drug interaction four core parameters were assessed: (i) evidence on the
interaction;  (ii)  clinical  relevance  of  the  potential  adverse  reaction  resulting  from  the
interaction;  (iii)  risk  factors  identifying  patient,  medication  or  disease  characteristics  for
which the interaction is of special importance; and (iv) the incidence of the adverse reaction.
On the basis  of  this  assessment the drug-drug interactions  for  inclusion in  the  CIS were
selected.  After  revision of  the drug combinations in the KNMP-CIS,  the Working Group
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judged 22% of the combinations to be not interacting and another 12% to be interacting but
not requiring action.
On the basis of this assessment the subset of drug combinations for which interaction
alerts are generated and the information on management of a drug interaction alert for users
of the CIS were adapted. When an alert is generated by the CIS, the user of the system is
supplied with comprehensive information on the four core parameters, the mechanism of the
interaction  and  critical  information  for  management  of  the  interaction  for  the  individual
patient.
J.Sogaard,  studied  Polypharmacy,  the  simultaneous  use  of  multiple  drugs,  is
associated  with  adverse  drug  reactions,  medication  errors,  and  increased  risk  of
hospitalization.  When the  number  of  concurrently  used  drugs  totals  five  or  more  (major
polypharmacy), a significant risk may be present. AIM: To analyse the interpractice variation
in the  prevalence  of  major  polypharmacy among listed  patients,  and to  identify possible
predictors of major polypharmacy related to the practice.23
 Methods:
Prescription data were retrieved from the Odense Pharmacoepidemiological Database,
and individuals subject to major polypharmacy were identified. The age and sex-standardized
prevalence rate of major polypharmacy was calculated for each practice in the County of
Funen  in  Denmark  (n  =  173),  using  the  distribution  of  age  and  sex  of  the  background
population  as  a  reference.  The  practice  characteristics  were  retrieved  from the  Regional
Health Insurance System. Possible predictors of major polypharmacy related to the general
practitioners (GPs) were analysed using backward stepwise linear multiple regression.
Results: 
A six-fold variation between the practices in the prevalence of major polypharmacy
was found (16 to 96 per 1000 listed patients; median = 42). Predictors related to the practice
structure, workload, clinical work profile, and prescribing profile could explain 56% of the
variation. CONCLUSION: A substantial part of the variation in major polypharmacy between
practices can be explained by predictors related to practice23.
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AIM AND OBJECTIVES
AIM AND OBJECTIVES
AIM:
• The aim of the present study was to Identification of drug drug interaction and 
modification of prescriptions in hospitalized geriatric patients in a tertiary care 
teaching hospital.
OBJECTIVES:
• To identification of drug drug interaction of prescriptions in hospitalized geriatric 
patients.
• To modify the prescriptions indicating the drug drug interactions in hospitalized 
geriatric patients in a tertiary care  hospital.
• To determine the drug drug interaction and the association between the number of 
drugs used per day per patient during hospitalized.
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PLAN OF THE WORK
          The present dissertation work was planned to conduct a Identification of drug drug
interaction and modification of prescription in hospitalized geriatric patients in a tertiary care
teaching  hospital.  The  dissertation  work  was  planned  to  be  conducted  in  Gejo  hospital,
kottayam,( dist), kerala.
The plan of work includes:
• Submission of the protocol for getting the approval from Ethical committee.
• To get oral consent from patients
• To design a data collection form.
• Collection of case histories of the patients with cutaneous  DDIs.
• Evaluvation of collected data.
• Drug drug interactions determined by using Multidrug interaction checker- Medscape.
• Data analysis with the help of computer using Microsoft Excel 2007.
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METHODOLOGY 
METHODOLOGY
STUDY DESIGN :
This study is prospective observational study. Identification of drug- drug interaction
and modification of prescriptions in hospitalized geriatric patients in a tertiary care teaching
hospital.
STUDY SETTING:
This study was conducted in Gejo hospital, kottayam (dist), kerala.
STUDY POPULATION :
A minimum of 100 patients admitted in the medicine wards were taken for the study.
DURATION OF STUDY:s
The study was carried out for a period of 6 months.
STUDY CRITERIA :
INCLUSION CRITERIA:
1. Patients of age 65 year and above.
2. Patients hospitalized for two days  and more.
EXCLUSION CRITERIA :
1. Patients below the age of 65 years.
2. Patients admitted to hospital before the commencement of the study.
STUDY VARIABLES :
1. Age
2. Gender
3. Current medical history( diagnosis)
4. Medicines prescribed
STUDY PROCEDURE :
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Research  type  was  observational  prospective.  The  datas  were  collected  from 105
cases  of  hospitalized geriatric  patients.  The  datas  were  collected  from patients  satisfying
inclusion criteria.
The  variables  analyzed  were  general  characteristics  of  the  patient  (gender,  age),
current  medical  history (diagnosis),  and  medicines  prescribed  during  hospitalization.  The
medication  use  of  geriatric  patients  during  hospitalization  were  recorded.  Then,  the
medications were classified according to pharmacological classification. To look for potential
drug drug interactions (DDIs) every combination of prescribed drugs were analyzed by using
the  Multidrug interaction checker – Medscape. DDIs is defined as a modification of the
effect of a drug when administered with another drug. The effect may be an increase or a
decrease in the action of either drug. 
The particular interaction may be the result of a chemical – physical incompatibility
of the two drugs or a change in the rate of absorption or the quality absorbed in the body, the
binding  ability  of  either  drug,  or  an  alteration  in  the  ability  of  receptor  sites  and  cell
membranes  to  bind  either  drug.  Most  adverse  drug-drug  interactions  are  either
pharmacodynamic or pharmacokinetic in nature. Depending on the severity of interaction,
DDIs are classified as major (an adverse effect can cause permanent damage or life risk),
Moderate (an adverse effect can harm and treatment is required), Minor (small or no clinical
effect,  with  no  treatment  required).  The matching  results  of  DDIs  is  classified  into  five
categories  (significance  level  1  to  5).  In  this  classification  ,  drug  interactions  are  at
significance level 1 when interaction  categories are divided into potentially severe or life
threatening  interaction;  occurrence  has  been  suspected,  established  or  probable  in  well
controlled  studies;  contraindicated  drug  combinations  also  comes  under  this  group.
Interaction  at  significance  level  2  can  cause  deterioration  in  a  patient’s  clinical  status;
occurrence has been suspected, established or probable in well controlled studies. 
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A potential drug drug interaction at significance level 3 presents a potential for
minor  effects;  occurrence  has  been  suspected,  established  or  probable  in  well
controlled  studies.  While drug drug  interaction at  significance  level4 might  cause
moderate-to-major  effects;  but  data  is  very  limited.  Then,  drug  interaction  at
significance level 5 may cause minor to major effects; occurrence is unlikely or there
is no good evidence of an altered clinical effect.
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OBSERVATIONS AND RESULTS
TABLE 1: AGE DISTRIBUTION OF GERIATRIC PATIENTS
Age group No. of cases Percentage
65-69 49 46.66
70-74 32 30.47
75-79 8 7.62
80-85 16 15.23
Total=105 100%
Of the total of 105 patients enrolled for the study, 49 patients were there in the age
group of 65-69 yrs (46.66%), 32 patients came under the age group of 70-74 yrs (30.47%), 8
patients came under the age group  of 75-79yrs(7.62%) and 16 patients came in 80-85 yrs age
group (15.23%).
It was also found that:
The average age of the total population was 73.65±5.77 yrs.
The average age of the male population was 74.16± 5.86yrs.
The average age of the female population was 72.93±5.60yrs.
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                                AGE DISTRIBUTION OF GERIATRIC PATIENTS
        FIGURE 1
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TABLE 2: GENDER DISTRIBUTION OF HOSPITALISED GERIATRIC PATIENTS
SEX NO. OF PATIENTS PERCENTAGE
Male 61 58.10%
Female 44 41.90%
Total 105 100%
A Total of 105 geriatric patients aged 65 yrs and above, and those who had satisfied
the inclusion criteria were entrolled for the study. Table 1 shows that, of the total 105 geriatric
patients enrolled in the study , 61 cases (58.10%) were males and 44 cases (41.90%) were
females. 
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GENDER DISTRIBUTION OF HOSPITALISED GERIATRIC PATIENTS
 
FIGURE 2
          
TABLE 3: NUMBER OF DRUGS PRESCRIBED PER DAY PER PATIENTS
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NO OF DRUGS
PRESCRIBED PER DAY
NO OF PATIENTS
RECEIVING DRUGS
PERCENTAGE OF TOTAL
POPULATION
1 0 0
2 6 1.90
3 12 11.42
4 13 12.38
5 26 24.76
6 25 23.80
7 7 6.66
8 4 3.80
9 5 4.76
10 4 3.80
11 2 1.33
Total =105 100%
From the data collected it was found that, of the total 105 patients enrolled in the
study,  31patients  were prescribed <5 medicines  per  day ,  5-8 drugs  were prescribed 63
patients  and 11 patients  were prescribed > 9 medicines per day figure3.
It was also found that the average number of drugs prescribed  per day  per patients
was 5.71± 1.99(±SD). This  result vary with a previous study conducted in which they found
that the average number of drugs prescribed per patients was 5.8±2.1.
                      NUMBER OF DRUGS PRESCRIBED PER DAY PER PATIENTS
ULTRA COLLEGE OF PHARMACY, MADURAI PAGE 40
OBSERVATIONS AND RESULTS
                                     FIGURE 3.
  
TABLE 4:  THE MOST COMMON DIAGNOSIS OF HOSPITALIZED GERIATRIC 
PATIENTS
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DISEASE CASES
Cardiovascular 18
Cerebrovascular disease 5
Diabetes 4
Respiratory disease 5
Infectious disease 4
Gastrointestinal disease 3
Musculoskel disorders 3
Vitamins 3
Table 4 shows that geriatric patients were commonly diagnosed with cardiovascular
disease  (18  cases),  followed    by  cerebrovascular  disease  (5cases),Diabetes  (1cases)  ,
respiratory  disease (4 cases),infectious disease (5cases), gastrointestinal disease  (4cases),
musculo- skeletal disorder (3cases) and vitamins (3cases)
THE MOST COMMON DIAGNOSIS OF HOSPITALIZED GERIATRIC
PATIENTS
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                                                                        FIGURE 4
TABLE 5: DISTRIBUTION OF NUMBER OF MEDICATION PRESCRIBED 
AMONG HOSPITALISED GERIATRIC PATIENTS
SL  NO CLASS OF DRUGS NO.OF DRUGS PERCENTAGE
1
Cardiovascular and 
haemopoetic system
98 18.91
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2 Vitamins and minerals 23 4.44
3
Gastrointestinal and 
hepatobilary system
102 19.69
4
Antibiotics 66 12.74
5
Respiratory system 59 11.38
6 Endocrine and metabolic system 87 16.79
7 Analgesics and NSAIDs 41 7.91
8 Central nervous system 26 5.01
9 Corticosteroid hormones 16 3.08
Total= 518 100%
Table 5 indicates that gastrointestinal and hepatobiliary  system drugs were  the  most
prescribed  drugs  for  geriatric  patients  (19.69%),  followed  by   cardiovascular   system
drugs(18.91%), drugs for endocrine  and metabolic system (16.79%)Antibiotics (12.74%),
Respiratory  system  drugs  (  11.38%),Analgesics  and  NSAIDs  (7.91%),  drugs  for  central
nervous system (5.01%) ,vitamins and minerals (4.44%), Corticosteroid hormones (3.08%).
Many studies have documented the most commonly prescribed class of medications used by
elderly patients was cardiovascular system drugs.
DISTRIBUTION OF NUMBER OF MEDICATION PRESCRIBED AMONG
HOSPITALISED GERIATRIC PATIENTS
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                                                                FIGURE 5
                       
 TABLE 6: NO. OF MEDICATION VS NO.OF  DDIS
NO OF DRUGS NO. OF  PATIENTS
NO. OF POTENTIAL
DDIS
PERCENTAGE
0-2 6 1 2.32
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3-4 25 9 18.62
5-6 51 26 60.46
7-8 11 2 4.65
9-10 9 4 9.30
11-12 3 2 4.65
Total =105 Total= 43 100
         A total of 43 DDIs were detected in the study. Every geriatric patient had consumed
more than 2 drugs per day and the patients were prescribed upto 11 drugs per day. From the
data  obtained  from the  prescriptions  the  patients  and  the  data  obtained  using  multidrug
interaction checker- Medscape.
It was found that the average number of potential drug –drug interactions per patient
was .5±.79. In  a previous study conducted, the average number of DDIs per  patient  was
found to be 1.38.
       
NO. OF MEDICATION VS NO. OF DDIS
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FIGURE 6
TABLE  7: CLASSIFICATION OF DDIS
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TYPE NO. OF  DDIS PERCENTAGE
Pharmacokinetic 18 41.86
Pharmacodynamic 16 37.20
Unknown 9 20.93
Total=43 100
     Based  on  the  mechanism,  interactions  were  classified  as  pharmacokinetic,
pharmacodynamic and unknown. A total of 43 interactions were identified in the study. Of
that 18 DDIs (41.86%) were due to pharmacokinetic interactions, 16 DDIs (37.20%) were
due to pharmacodynamic interactions and for 9 DDIs (20.93%) were unknown.
                                                 CLASSIFICATION OF DDIS
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          FIGURE 7.
TABLE 8: GENDER DISTRIBUTION OF DRUG –DRUG INTERACTIONS
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SEX
NUMBER OF
PATIENTS WITH
POTENTIAL DDI
NUMBER OF
PATIENTS
ENROLLED
PERCENTAGE
Male 20 61 32.78%
Female 11 44 25%
Total 31 105 29.52%
Table and figure  8 shows that, of the total 61 males included  in the  study  22patients
(32.78%) was prescribed with medicines causing  DDIs and of the 44 females enrolled in the
study 19 patients (25%) were prescribed with medications  to cause drug drug interactions.
And 29.5% of total population were prescribed with medications causing DDIs.
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GENDER DISTRIBUTION OF DRUG DRUG INTERACTIONS
TABLE NO 9 :DETAILS OF PHARMACOKINETIC INTERACTIONS OBSERVED:
SL
NO
DRUG INTERACTION TYPE OF
REACTION
MECHANISM MODIFICATION
1. RANITIDINE-METRONIDAZOLE
Pharmacokinetic Ranitidine reduces
the absorption of 
Metronidazole
Omeprazole was 
suggested instead 
of Ranitidine
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2 LOPERAMIDE-THEOPHYLLINE
Pharmacokinetic Loperamide 
delays the 
absorption of 
theophylline
Should not be 
administered 
together
3 ALLOPURINOL-CLOPROPAMIDE
pharmacokinetic Allopurinol 
increases the half 
life of 
Clopropamide
Decrease the dose 
of Allopurinol
4 RANITIDINE-KETOCONAZOLE
Pharmacokinetic Ranitidine reduces
the absorption of 
ketoconazole
Proton pump 
inhibitors to be 
used insted of 
ranitidine
5 CIPROFLOXACIN-DIAZEPAM
Pharmacokinetic Ciprofloxacin 
increases the level
of diazepam
Norfloxacin to be 
used instead of 
Ciprofloxacin
6 METOPROLOL- THEOPHYLLINE
Pharmacokinetic Metoprolol 
decreases 
theophylline 
metabolism
Dose adjustment- 
theophylline dose 
to be reduced
7 METOCLOPRAMIDE-DIGOXIN
Pharmacokinetic Metoclopramide 
reduces digoxin 
absorption
Promethazine  
suggested instead 
of metoclopramide
8 ASPIRIN – METHYLPREDNISOLON
E
pharmacokinetic Methyl 
prednisolone 
stimulats liver 
metabolisam of 
aspirin & 
increases renal 
eliminations
Moniter aspirin 
concentration when
adding methyl 
prednisolone
9 METOCLOPRAMIDE- PARACETAMOL
Pharmacokinetic Metoclopramide 
increase the rate 
of absorption of 
paracetamol
Promethazine to be
used instead of 
metoclopramide
10
WARFARIN- 
RIFAMPICIN
Pharmacokinetic Increase hepatic 
microsomal 
enzyme 
metabolisam of 
warfarin by 
rifampicin
Rifampin are 
discontinued to 
avoid  excessive 
bleeding
11 SIMVASTATIN-DIGOXIN
Pharmacokinetic Simvastatin 
increases the 
serum level of 
Digoxin
Should not be 
administered 
together
TABLE NO:10 DETAILS OF PHARMACODYNAMIC INTERACTIONS 
OBSERVED:
SL
N
DRUG INTERACTION TYPE OF
REACTION
MECHANISM MODIFICATION
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O
1 ENALAPRIL-SPIRANOLACTONE
Pharmcodynamic Pharmacodynamic 
synergism,Risk of 
hyperkalemia
Frusamide 
suggested instead of
Spiranolactone
2 ENALAPRIL- GLIMPRIDE
Pharmacodynami
c
Enalapril increases 
the effects of 
glimipride
Should not be 
administered 
together
3 OMEPRAZOLE- LOSARTAN
Pharmacodynami
c
Omeprazole 
descreases effects of
losartan
Should not be 
administered 
together
4 RIFAMPICIN-THEOPHYLLINE
Pharmacodynami
c
Rifampicin reduces 
theophylline effect
Should not be 
administered 
together
5
HYDROCHLOROTHIAZIDE
-ACARBOSE
Pharmacodynami
c
Hydrochlorothiazid
e decrease the 
effects of acarbose
Frusemide was used
instead of 
Hydrochlorothiazid
e
6
CLARITHROMYCIN- 
CLOPIDOGREAL
Pharmacodynami
c
Clarithromycin 
decreases the level 
or effects of 
clopidogrel by 
affecting hepatic 
metabolisam
Should not be 
administered 
together
7 NIFEDIPINE- CLOPIDOGREL
Pharmacodynami
c
Nifedipine will 
decrease the level or
effect of clopidogrel
by affecting hepatic 
intestinal enzyme 
CYP 3A4 
metabolisam
Should not 
administered 
together
8 PHENYTOIN- AZITHROMYCIN
Pharmacodynami
c
Phenytoin will 
descrease 
azithromycin level
Should not 
administered 
together
9 NIFEDIPINE- ATORVASTATIN
Pharmacodynami
c
Nifedipine will 
increase the effect 
atorvastatin by 
affecting hepatic 
enzyme  CYP3A4 
metabolisam
Should not 
administered 
together
10
PANTOPRAZOLE- 
CLOBAZAM
Pharmacodynami
c
Pantoprazole will 
increase the effectof
clobazam
Dose adjustment  
may  be required
11 VITAMIN E- WARFARIN
Pharmacodynami
c
Vitamin e enhance 
anticoagulant 
effects  of warfarin
Vitamin E  dose will
be reduced
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12 PHENOBARBITAL- CLOPIDOGREL
Pharmacodynami
c
Phenobarbital  
increase in 
antiplatelet  effects 
of clopidogrel
Clopidogrel  dose 
will be redused
13 DICLOFENAC- ASPIRIN
Pharmacodynami
c
Aspirin and 
diclofenac both 
increase 
anticoagulation
Should not  be 
administered 
together
14 CIPROFLOXACIN –PROPRANOLOL
Pharmacodynami
c
Ciprofloxacin 
increases the effects
of  propranolol
Propranolol dose 
will be adjusted
15 AMOXICILLIN – WARFARIN
Pharmacodynami
c
Amoxicillin 
increases effects of 
warfarin
Should not be 
administered 
together
16 ZAFILUKAST- 
THEOPHYLLINE
Pharmacodynami
c
Zafilukast will 
increase the level or
effect of 
theophylline by 
affecting hepatic 
/intestinal enzyme 
CYP3A4 
metabolisam
Concurrent 
administration 
should be avoided
17 ATORVASTATIN- BUDESONIDE Pharmacodynami
c
Atorvastatin  
increase the effect 
of glycoprotein
Concurrent 
administration 
should be avoided
TABLE NO:11 DETAILS OF MISCELLANEOUS INTERACTIONS 
OBSERVED
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1 METFORMIN- 
FUROSEMIDE
Un known
Metformin descreases levels 
of furosamide by unspecified 
interaction mechanisam
Should not  be 
administered 
together
2
CALCIUM 
CARBONATE- 
ATENOLOL
Unknown
Calcium carbonate descreases
effects of atenolol by 
unspecified interaction 
mechanisam
Should not  be 
administered 
together
3 GLIMEPIRIDE- 
DICLOFENAC
Unknown
Diclofenac  increases effects 
of glimepiride by unknown 
mechanisam
Should not be 
administered at 
same time
TABLE 12: FREQUENCY OF  DRUGDRUG INTERACTION
FREQUENCY OF DRUG-DRUG
INTRACTION
NO.OF CASES PERCENTAGE
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No.interaction 74 70.47
1 0 0
2 1 0.95
3 3 2.85
4 6 5.71
5 9 8.57
6 8 7.61
7 1 0.95
8 0 0
9 1 0.95
10 1 0.95
11 1 0.95
105 100
74 (70.47%) cases did not had any combination of medicines to cause DDIs.  The
results were comparable to a previous study, in which , of a total of 100 patients taken for the
study, 74 cases did not had any incidences of DDIs.
                                 
  FREQUENCY OF DRUG DRUG INTERACTION
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TABLE 13: ACTIVE SUBSTANCES MOST FREQUENTLY INVOLVED IN  
DRUGDRUG INTERACTIONS
SL NO ACTIVE SUBSTANCE NUMBER OF  DDIS
1 Ranitidine 1
2 Loperamide 3
3 Allopurinol 1
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4 Hydrochlorthiazide 1
5 Rifampicin 1
6 Omeprazole 1
7 Simvastatin 1
8 Metoprolol 1
9 Enalapril 2
10 Ciiprofloxacin 3
11 Diclofenac 2
12 Clopidogrel 4
13 Aceclofenac 1
14 Warfarin 2
15 Zafirlukast 1
16 Phenytoin 1
17 Prednesolone 1
18 Atenolol 1
19 Aspirin 2
20 Amoxycillin 2
21 Metoclopramide 1
22 Nefidipine 1
23 Atorvastatin 3
24 Metronidazole 1
25 Calcim carbonate 1
26 Phenobarbitone 1
27 Furosemide 1
28 Metformin 1
29 Heparin 1
30 Vitamin E 1
31 pantoprazole 1
Table 10 shows the ten active substances most frequently involved in potential DDIs
in the study. Several cardiovascular  drugs were the most frequently involved  (clopidogrel,
low dose aspirin,  Heparin,  Atorvastatin  ,Enalapril,  Diltiazem),  followed by ciprofloxacin,
CNS  drug  (phenytoin),  gastrointestinal  (pantoprazole),  insulin  and  theophylline.  Elderly
patients are the population at the highest risk of  potentialDDIs.They frequently take many
drugs  (polypharmacy),  have  several  co-  morbidities,  and  might   not   maintain  adequate
nutritional status. The application of evidence based medicine tends to increase the number of
drugs prescribed to treat one disorder. Additionally, age related changes in pharmacokinetics
and  pharmacodynamic  characteristics,  including  impairment  in  many  organ  functions
(particularly kidney and liver ) increase the complexity of drug interactions in elderly people.
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ACTIVE SUBSTANCES MOST FREQUENTLY INVOLVED IN DRUG DRUG 
INTERACTIONS
                       FIGURE 10.
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TABLE 14:COMBINATION OF DRUGS MOST COMMONLY INVOLVED IN DDIS
SL
NO.
DRUG COMBINATION SEVERITY
NO OF
INTERACTIONS
1 Clopidogrel- Atorvastatin Moderate 21
2 Clopidogral- Heparin Moderate 17
3 Heparin- Aspirin Moderate 12
4 Clopidogrel- pantoprazole Major 11
5 Iron- Mg/Al/Ca Moderate 8
6 Ciprofloxacin- Insulin Moderate 6
7 Atorvastatin- Diltiazem Moderate 6
8 Clopidogrel- Omeprazole Major 5
9 Phenytoin-Folic acid Moderate 5
10 Phenytoin-Thenophylline Moderate 4
Clopidogrel-Atorvastatin was  the most frequently involved drug combination causing
DDIs(21  cases),  followed  by  Clopidogrel-Heparin  (17  cases),  Heparin-Aspirin(12cases),
Clopidoggrel-Pantoprazole(11cases),  Iron-Mg/Al/Ca(8cases),  Ciprofloxacin-  Insulin(6
cases),Atorvastatin-  Diltiazem  (6cases),  Clopidogrel-Omeprazole(5cases),  Phenytoin  –
Theophylline (4cases).
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TABLE 15: NUMBER OF DRUGS VS DRUG – DRUG INTERACTION YES/ NO 
CROSS TABULATION
NO.OF DRUGS
POTENTIAL DRUG
DRUGINTERACTION TOTAL
YES NO
Upto 5 drugs 20 (33.33%) 40 (54.05%) 60(57.14%)
6-8 drugs 8 (13.33%) 16 (21.62%) 24(22.85%)
9-11 drugs 3(14.28%) 18 (24%) 21(20%)
Total 31 74 105(100%)
Table  clearly  indicates  that,  as  the  number  of  drugs  prescribed  to  the   patient
increases,  the percentage   of  number of  cases  of  potential  of  DDIs also increases.  This
increasing trend  of  DDIs  with  increase  in  the  number  of  medication  .  A previous  study
conducted also indicated a positive relationship between the number of drugs and number of
drugs and number of drug drug interactions.
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NUMBER OF DRUGS VS DRUG DRUG INTERACTION YES /NO CROSS
TABULATION
     FIGURE 11.
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DISCUSSION 
DISCUSSION
 A total of 105 geriatric patients were included in the study. Of which, 58.10% were
males and 41.90% were females.
 From the study, it was found that, the average age of the study group was 73.65±
5.77yrs. In male gender, the average age was found to be 74.16±5.86 yrs, and the
average age of the female gender was found to be 72.93 ± 5.60yrs.
 From the  data  collected  from the  case  sheet  of  the  patients,  most  of  the  patient
consumed more than 4 drugs per day and the average number of drugs consumed per
day per patient was found to be 5.8 ± 2.1.
 The  most  common  diagnosis  of  hospitalised  geriatric  patients  was  cardiovascular
diseases,  followed  by  cerebrovascular  diseases,  Endocrine  disease  (especially
diabetes), Respiratory diseases, infectious disease and gastrointestinal disorders. 
 The gastrointestinal and hepatobiliary  system drugs were  the  most prescribed drugs
for     geriatric patients (19.69%), followed by  cardiovascular  system drugs(18.91%),
drugs for endocrine  and metabolic system (16.79%)Antibiotics (12.74%), Respiratory
system drugs ( 11.38%),Analgesics and NSAIDs (7.91%), drugs for central nervous
system (5.01%) ,vitamins and minerals (4.44%), Corticosteroid hormones (3.08%).
Many studies have documented the most commonly prescribed class of medications
used by elderly patients was cardiovascular system drugs.
 A total of 43 DDIs were detected in the study and the average number of potential
drug drug interactions per patient was found to be .5±7.9(±SD). It was also found that,
74 case  did not have any combination of medicines to cause potential DDIs.
 Of  a  total  of  43  potential  DDIs  detected  in  the  study,  41.86%  were  due  to
pharmacokinetic  interaction  between  the  drugs,  37.20%  were  due  to
pharmacodynamic  interaction  between  the  drugs  and  for  the  remaining  cases
(20.93%), the reason for the interaction was unknown.
 Of a total of 61 males included in the study, 20 males had drugs causing potential
DDIs  (32.78)  and  of  the  44 females  included in  the study,  19 females  had drugs
causing potential DDIs (25%).
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 The active substances most frequently involved in  DDIs were Cardiovascular drugs
(clopidogrel, low dose Aspirin, Heparin, Atorvastatin, Enalapril, Diltiazem), followed
by ciprofloxacin,  CNS drug (phenytoin),  gastrointestinal  (pantoprazole),Insulin and
Theophylline.The combination of Clopidogrel Atorvastatin caused the most number
of  DDIs,  followed  by  Clopidogrel  Heparin,  Heparin  Aspirin  and  Clopidogrel
pantoprazole.
 The combination of  Clopidogrel, pantoprazole and Clopidogrel omeprazole were the
most severe DDIs (Major) detected in the study.
ULTRA COLLEGE OF PHARMACY, MADURAI PAGE 65
CONCLUSION 
CONCLUSION
The  incidence  of  DDIs  in  hospitalized  geriatric  patients  was  substantial.  The
number of DDIs do not depend only on the number of drugs prescribed, it also depend on the
combination of drugs prescribed which has the potential to cause interaction and other factors
include the age related changes in the pharmacokinetics and pharmacodynamic characteristics
of the elderly patient. To reduce DDIs, the number of medications for the geriatric patients
should be properly controlled and it is recommended to eliminate all medications without
therapeutic  benefit,  goal  or  indication.  Beside,  pharmacist  should  increase  their  role  in
managing medication therapy through collaboration with other health care professionals to
prevent and resolve drug drug interaction problem.
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